Gene/Cell Therapies: Sponsors Must Plan For Long-Term Safety Follow-Up Even If They Fold
In final guidance documents on development of CAR-T cell products and human genome therapies incorporating genome editing, US FDA says that sponsors should plan for continued follow-up, with funding, even if they cease operations or withdraw the IND.
